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(FAP) can hydrolyze the post-
proline bond. We identified en-
dogenous substrates of FAP in
fibroblasts that were previously
naive to both FAP and its pro-
teolytic activity. FAP-dependent
cleavage sites were identified in
many extracellular matrix (ECM)
and ECM-associated proteins
including collagens and lysyl oxi-
dase-like-1, and CSF-1, CXCL-5
and C1qT6. Quantitative pro-
teomic analysis implicated FAP
in ECM-cell interactions, coagu-
lation and metabolism. This
study greatly expands the reper-
toire of FAP substrates and
shows that FAP has a role in
coagulation in the mouse.
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knockout mouse derived embryonic fibroblasts stably transduced with enzymatically active or inactive FAP.
• Terminal amine isotopic labelling of substrates (TAILS) based degradomics identified cleavage sites
in collagens, and many other extracellular matrix (ECM) and associated proteins.
• Cleavages of lysyl oxidase-like-1, CXCL-5, CSF-1 and C1qT6 by FAP were confirmed in vitro.
• Differential metabolic labelling coupled with quantitative proteomic analysis implicated FAP in regulating
proteins that are associated with ECM, ECM-cell interactions, coagulation, metabolism and wound healing.
Research
Zhang et al., 2019, Molecular & Cellular Proteomics 18, 65–85
January 2019 © 2019 Zhang et al. Published under exclusive license by The American Society for
Biochemistry and Molecular Biology, Inc.
https://doi.org/10.1074/mcp.RA118.001046










Identification of Novel Natural Substrates of
Fibroblast Activation Protein-alpha by
Differential Degradomics and Proteomics*□S
Hui Emma Zhang‡§‡‡‡, Elizabeth J. Hamson‡§‡‡‡, Maria Magdalena Koczorowska¶,
Stefan Tholen¶, Sumaiya Chowdhury‡§, Charles G. Bailey‡§, Angelina J. Lay‡§,
Stephen M. Twigg§, Quintin Lee‡§, Ben Roediger‡§, Martin L. Biniossek¶,
Matthew B. O’Rourke**, Geoffrey W. McCaughan‡§, Fiona M. Keane‡§,
Oliver Schilling‡‡§§¶¶§§§¶¶¶, and Mark D. Gorrell‡§§§§
Fibroblast activation protein-alpha (FAP) is a cell-surface
transmembrane-anchored dimeric protease. This unique,
constitutively active serine protease has both dipeptidyl
aminopeptidase and endopeptidase activities and can hy-
drolyze the post-proline bond. FAP expression is very low
in adult organs but is upregulated by activated fibroblasts
in sites of tissue remodeling, including fibrosis, athero-
sclerosis, arthritis and tumors. To identify the endoge-
nous substrates of FAP, we immortalized primary mouse
embryonic fibroblasts (MEFs) from FAP gene knockout
embryos and then stably transduced them to express
either enzymatically active or inactive FAP. The MEF se-
cretomes were then analyzed using degradomic and pro-
teomic techniques. Terminal amine isotopic labeling of
substrates (TAILS)-based degradomics identified cleav-
age sites in collagens, many other extracellular matrix
(ECM) and associated proteins, and lysyl oxidase-like-1,
CXCL-5, CSF-1, and C1qT6, that were confirmed in vitro.
In addition, differential metabolic labeling coupled with
quantitative proteomic analysis also implicated FAP in
ECM-cell interactions, as well as with coagulation, metab-
olism and wound healing associated proteins. Plasma
from FAP-deficient mice exhibited slower than wild-type
clotting times. This study provides a significant expansion
of the substrate repertoire of FAP and provides insight
into the physiological and potential pathological roles of
this enigmatic protease. Molecular & Cellular Proteom-
ics 18: 65–85, 2019. DOI: 10.1074/mcp.RA118.001046.
Fibroblast activation protein-alpha (FAP)1 is a unique post-
proline peptidase, which possesses both endopeptidase ac-
tivity and dipeptidyl aminopeptidase (DPP) activity, allowing it
to cleave a peptide bond two or more residues from the N
terminus of a peptide or protein (1, 2). FAP is expressed at the
cell surface and also shed. Both forms are enzymatically
active and have similar substrate preferences (3). Although
FAP has attracted much interest because of potential roles in
fibrosis, cell migration and apoptosis and as a potential
marker for many cancers (4–6), few of its natural substrates
have been identified (1, 4, 7–11).
Only three of the identified endopeptidase substrates of
FAP are physiological substrates, namely denatured type I
collagen (1, 12), 2-antiplasmin (3) and fibroblast growth fac-
tor-21 (FGF-21) (8–10). By screening known DPP4 substrates
(7), and then measuring cleavage in plasma (13), we have
previously identified four physiological DPP-type substrates
of FAP, namely neuropeptide Y (NPY), substance P, peptide
YY (PYY) and B-type natriuretic peptide (BNP). NPY was
found to be the most efficiently cleaved substrate of both
human and mouse FAP, whereas all four peptides were found
to be efficiently cleaved by endogenous DPP4, indicating that
the in vivo degradomes of FAP and DPP4 differ (13).
Identification of additional FAP substrates is essential to
fully elucidate its role as a protease. FAP is implicated in
fibrinolysis because human 2-antiplasmin has 4-fold in-
creased activity following FAP mediated cleavage (14). Inhi-
bition of FAP increases the levels of active FGF-21 in obese
mice more than in lean mice, demonstrating a metabolic
benefit of FAP inhibition (15), which might be exploited for
treating diabetes. Up-regulated expression of FAP is predom-
inantly associated with disease states, including but not lim-
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ited to tumorigenesis, fibrotic conditions and atherosclerosis
(5, 6, 16, 17). Therefore, FAP is emerging as a promising
marker of disease and much attention focuses upon exploit-
ing this protease as a therapeutic target (4–6, 18). Neverthe-
less, the functions of FAP in both physiological and patholog-
ical processes remain unclear. Improved knowledge of the
basic biology of FAP is necessary to broaden our perspective
on potential outcomes of targeting this protease and predict
potential impacts on the proteome when FAP enzyme activity
is inhibited or ablated.
Several degradomic techniques have been developed for
the discovery of physiological substrates of proteases for the
DPP4 family (4, 19–22). The overall aim of this study was to
identify novel substrates of FAP using an unbiased, global,
degradomic technique (terminal amine isotopic labeling of
substrates, or TAILS), a more targeted data mining approach,
and a proteome comparison (stable isotope labeling by amino
acids in cell culture, or SILAC). Through our identification of
FAP substrates and subsequent investigation of the biological
consequence of cleavage of these proteins, knowledge and
understanding of the physiological role of FAP was enhanced.
EXPERIMENTAL PROCEDURES
Experimental Design and Statistical Rationale—A total of five rep-
licate analyses were conducted for the differential proteomic investi-
gation of the FAP enzyme-active (e) and FAP enzyme-inactive (e)
mouse embryonic fibroblasts (MEFs) (see below for details of cell
generation). A total of three replicate analyses were conducted for the
differential N-terminomic investigation of the FAP e and FAP e
MEFs (see below for details of cell generation). Statistical analysis
using linear models for microarray data (limma) (23) allows for the use
of linear models to assess differential expression in the context of
multifactor designed experiments. In addition, limma enables analy-
ses of complex experiments involving comparisons between many
peptides simultaneously in a small sample size, including multiple
testing correction. Following the calculation of moderated-t-tests,
proteins or cleavage sites with a p value  0.05 and a quantitative
alteration  50% (either increase or decrease), were considered as
being significantly affected.
Generation of FAP Enzyme-active (e) and FAP Enzyme-inactive
(e) MEFs—MEFs were isolated from FAP gene knockout (GKO)
mouse embryos aged 13.5 days. In this FAP GKO mouse strain, FAP
has been deleted in both alleles and exons 3 to 26 are absent (24, 25).
Primary MEFs were immortalized by transduction with the pFU-SV40-
LTpuro lentiviral vector encoding the SV40 large T antigen then se-
lected in puromycin (26). These MEFs were then divided into three
cultures and transduced with a lentiviral vector pCCLteteGFP to
express green fluorescent protein (GFP) as an empty vector control,
or linked to one of two human FAP (hFAP) constructs using a picor-
naviral 2A peptide (27). PCR was used to amplify enzyme active
(hFAP e) and inactive (hFAP e; serine724alanine) constructs from
GFP-FAP (28) using the primers hFAP-5BmgBI 5-GTGGAA-
GAAAACCCCGGGCCCATGAAGACTTGGGTAAAAATCG-3 and hFAP-
3BstBI 5-AAAAGATTCGAAGTTTAAACTTAGTCTGACAAAGAGA-
AACAC-3. PCR fragments (2324bp) were generated using Phusion
polymerase (Finnzymes; Thermo Scientific, Waltham, MA) phospho-
rylated with T4 polynucleotide kinase (NEB, Ipswich, MA) and di-
gested with BstBI. The pCCLteteGFP2Aluc2 lentiviral vector was cut
with BmgBI/ClaI to clone in hFAP e and hFAP e genes. Trans-
duced MEFs were selected by GFP-based cell sorting using a BD
Biosciences FACS Aria flow cytometer and expanded as pools. An
endopeptidase activity assay was performed on the cells and secre-
tomes of FAP e and FAP e MEFs using the fluorogenic substrate
Z-Gly-Pro-AMC (1 mM; Bachem, Bubendorf, Switzerland), in the pres-
ence or absence of a non-selective DPP inhibitor (Val-boro-Pro at 50
M (kind gift from WW Bachovchin, Boston, MA) and a PEP-selective
inhibitor (S17092 at 1 M; Sigma-Aldrich, St Louis, MO).
Collection of Cell Conditioned Medium—Cell conditioned medium
(CCM) was generated from three biological replicates of FAP e and
e MEF cell lines. Cells were grown in 15 cm dishes to a confluency
of 70% in 20 ml culture medium. After 16 h incubation in serum-free
supplemented DMEM (Thermo Scientific) without phenol red, CCM
was harvested in the presence of the following protease inhibitors:
0.01 mM trans-epoxysuccinyl-l-leucylamido (4-guanidino) butane
(E64; Sigma-Aldrich), 5 mM ethylene-diaminetetraacetic acid (EDTA;
Sigma-Aldrich) and 1 mM phenylmethylsulfonylfluoride (PMSF; Sig-
ma-Aldrich). CCM was centrifuged at 1500 rpm and filtered using a
0.2 m filter (Amicon; EMD Millipore, Billerica, MA) to remove dead
cells and debris. HEPES buffer (Sigma-Aldrich) (pH 7.5) was added to
a final concentration of 100 mM and the CCM mildly denatured and
reduced with 5 mM dithiothreitol (DTT) (Sigma-Aldrich) at room tem-
perature for 1–2 h. Free sulfide groups were alkylated by incubation
with 20 mM iodoacetamide (IAA) (Sigma-Aldrich) for 2 h at room
temperature in the dark, then 5 mM DTT was added for 15 min at room
temperature to quench any remaining IAA.
Terminal Amine Isotopic Labeling of Substrates (TAILS)—TAILS
was performed as described previously (29–31). Briefly, CCM was
concentrated then precipitated with trichloroacetic acid. The protein
pellet was re-solubilized in ice-cold 2 M guanidine hydrochloride using
ultrasonication. After adjusting the pH to 7.5 using HEPES, the sam-
ples were reduced and alkylated again as described above. Protein
was then differentially labeled with 40 mM heavy [d(2)13C] or light
[d(0)12C] formaldehyde (Cambridge Isotope Laboratories, Andover,
MA) in the presence of 40 mM sodium borohydride (for 18 h at 37 °C).
After quenching excess reagents with 50 mM Tris (for 2 h at 37 °C),
samples were mixed at equal amounts, acetone precipitated and
resolubilized with 100 mM ice-cold NaOH. The pH was adjusted to 8
with HEPES-free acid and samples were digested overnight with
mass spectrometry grade trypsin (Worthington, Lakewood, NY) at
37 °C. Labeled peptides were enriched by a negative selection step
using a dendritic polyglycerol aldehyde polymer, as described (32).
Blocked N-terminal peptides (unbound) were physically separated
from the polymer-captured peptides via a 10 kDa molecular weight
cut-off filter (Amicon; EMD Millipore). Flow through and filtrate were
1 The abbreviations used are: FAP, fibroblast activation protein;
APTT, activated partial thromboplastin times; BNP, B-type natriuretic
peptide; CAF, cancer associated fibroblast; C1qT6, complement C1q
tumor necrosis factor-related protein 6; CCL-2/MCP-1, monocyte
chemoattractant protein-1; CCM, cell conditioned medium; CCR,
C-C motif chemokine receptor; CN-I, type 1 collagen; CSF, colony-
stimulating factor; CXCL, C-X-C motif chemokine ligand; DPP, dipep-
tidyl peptidase; DTT, 1,4-dithiothreitol; ECM, extracellular matrix;
FGF, fibroblast growth factor; GFP, green fluorescent protein; GKO,
gene knockout; IAA, iodoacetamide; IL, interleukin; limma, linear
models for microarray data; LOX-L, lysyl oxidase homolog; MALDI,
matrix assisted laser desorption ionisation; MEF, mouse embryonic
fibroblast; MMP, matrix metalloproteinase; NPY, neuropeptide Y;
PEP, prolyl endopeptidase; PMSF, phenylmethylsulfonylfluoride; PT,
prothrombin times; PYY, peptide YY; SILAC, stable isotope labeling
with amino acids in cell culture; TGF, transforming growth factor;
TAILS, terminal amine isotopic labeling of substrates; TIMP, inhibitor
of matrix metalloproteinase.
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combined and desalted using a reverse phase C18 column (Sep-Pak,
Waters, Milford, MA).
Stable Isotope Labeling by Amino Acids (SILAC) In Cell Culture—
The SILAC protocol was performed as described (33). Briefly, MEFs
were grown in heavy or light labeled DMEM (minus L-Arg and L-Lys;
Silantes, Munich, Germany) supplemented with 10% dialyzed FCS
and glutamine containing either L-arginine (Arg0) and L-lysine (Lys0)
“light” or 13C6 15N4 L-arginine (Arg10) and 13C6 15N2 L-lysine (Lys8)
“heavy” for at least five cell population doublings. After 16 h of
seeding cells in heavy or light medium, CCM was collected as de-
scribed above. Differentially labeled CCM was mixed at a ratio of 1:1
and concentrated to 200 l using Amicon® Ultra 50 ml 5 kDa
centrifugal filters (EMD Millipore), 4000 g, 4 °C. Samples were run on
12–16% SDS-PAGE (Criterion Tris-HCL gel, Bio-Rad and NuPage®
buffers, Thermo Scientific) and proteins visualized using a Colloidal
Blue staining kit (Thermo Scientific). After destaining, gels were cut
into 1 mm cubes and further destained with three rounds of 0.1 M
ammonium bicarbonate, 50% acetonitrile and 50 mM ammonium
bicarbonate then 100% acetonitrile, sonicating on ice. Gel pieces
were digested with sequencing grade trypsin (Worthington) at pH 7.5,
overnight at 37 °C. After digestion, peptides were eluted from the gel
with 100% ethanol, samples were then concentrated using a Speed-
vac concentrator (model 5301, Eppendorf, Hamburg, Germany) and
desalted using a reversed phase C18 column (GRACE-VYDAC, Deer-
field, IL).
Liquid Chromatography-MS/MS and Data Analysis—TAILS sam-
ples were then prefractionated by high performance liquid chroma-
tography (HPLC) using a strong cation exchange column (SCX;
PolyLC, Columbia, MD). Peptides were eluted in a linear gradient with
increasing concentration of 5 mM KH2PO 1 M KCl 25% acetonitrile pH
2.7; 10–14 fractions were collected and desalted using self-packed
C18 STAGE tips (Empore; 3 M, St Paul, MN) (34). Differential proteom-
ics samples were pre-fractionated by SDS-PAGE as described pre-
viously (31). For nanoflow-LC-MS/MS analysis, samples for quantita-
tive proteomic comparison were analyzed on a Qstar Elite (AB Sciex,
Framingham, MA) and TAILS samples on an Orbitrap XL (Thermo
Scientific GmbH, Bremen, Germany) mass spectrometer. Both instru-
ments were coupled to an Ultimate3000 micro pump (Thermo Scien-
tific) with a flow rate of 300 nL/min each. Buffer A was 0.5% (v/v)
acetic acid, and buffer B was 0.5% (v/v) acetic acid in 80% (v/v)
acetonitrile (water and acetonitrile were at least HPLC gradient grade
quality). A gradient of increasing organic proportion was used for
peptide separation. Column-tips with 75 m inner diameter and a
length of 11 cm were self-packed with Reprosil-Pur 120 ODS-3 (Dr.
Maisch, Ammerbuch, Germany). The MS operated in data dependent
mode, with the SMART being used for the QSTAR Elite. For the
Orbitrap XL, each MS scan was followed by a maximum of five
MS/MS scans; and for the Qstar Elite three MS/MS scans.
Raw QSTAR LC-MS/MS data in wiff format (quantitative proteomic
comparison, SILAC) was converted to the mzXML (35) format, using
mzWiff (version 4.3.1, http://sourceforge.net/projects/sashimi/files/
mzWiff%20(Analyst%20converter), with centroiding of MS1 and MS2
data, precursor charge determination, and deisotoping of MS2 data.
X!Tandem (version 2013.09.01) (36) was used for spectrum to se-
quence assignment. The proteome database consisted of (1) mouse
UniProt sequences (without isoforms) downloaded from UniProt on
April 15th, 2016, (2) the sequence of human FAP, and (3) the con-
taminant database of MaxQuant (total of 50935 entries). It was ap-
pended with an equal number of shuffled decoy entries derived from
the original human protein sequences. The decoy sequences were
generated with the software DB toolkit (37). X!Tandem parameters for
analysis of QSTAR data included: asymmetric precursor mass error of
50–150 ppm, fragment ion mass tolerance of 0.2 Da, tryptic cleav-
age specificity with no missed cleavage sites, residue modifications:
cysteine carboxyamidomethylation (57.02 Da), variable modifica-
tions were isotope-labeled (6.02 Da) arginine and lysine. X!Tandem
results were further validated by PeptideProphet (38). Peptides were
assembled to proteins using ProteinProphet (39) at a false discovery
rate of less than 1%. XPRESS was used for relative peptide and
protein quantification (40). Mass tolerance for quantification was 0.1
Da. Ratios of each dataset were calculated as FAP-active/FAP-inac-
tive and log2-transformed. Five biological replicates were analyzed.
Prior to limma statistical analysis (see Statistical Rationale above),
samples were mean normalized. No outlier removal was performed.
Isoform quantification was solved by the well-established XPRESS
algorithm, which assigns weights to peptides accordingly.
Raw Orbitrap-XL LC-MS/MS data (TAILS, stable isotope labeling
with dimethylation) was converted to the mzXML (35) format, using
msconvert (41) with centroiding of MS1 and MS2 data and deiso-
toping of MS2 data. For spectrum to sequence assignment X!Tandem
(version 2013.09.01) (36) was used, with the proteome database
described above. X!Tandem parameters for analysis of Orbitrap-XL
data included: precursor mass error of  10 ppm, fragment ion mass
tolerance of  0.4 Da, semi-ArgC specificity with up to three missed
cleavages, static residue modifications: cysteine carboxyamidom-
ethylation (57.02 Da); lysine and N-terminal dimethylation (light
formaldehyde 28.03 Da; heavy formaldehyde 34.06 Da or 36.08 Da;
no variable modifications. These X!Tandem results were further vali-
dated by PeptideProphet at a confidence level of  95%. XPRESS
was used for relative peptide quantification (36, 38, 40). Mass toler-
ance for quantification was 0.015 Da. Ratios of each data set were
calculated as FAP-active/FAP-inactive and log2-transformed. Three
biological replicates were performed. Prior to limma statistical anal-
ysis (see Statistical Rationale above), samples were mean normalized.
No outlier removal was performed. An in-house PERL computer script
(downloadable at http://www.mol-med.uni-freiburg.de/mom/schilling/
TAILS_v21_xpress-only/at_download/file) then filtered for peptides that
had a non-tryptic N terminus generated. Like the original PICS proce-
dure (42), the script then determines bioinformatically, through database
lookup, the corresponding prime- or non-prime sequence. The script
also used Uniprot and Gene Ontology annotation to distinguish se-
creted proteins. Web-PICS was used to generate heat-map style rep-
resentation of protease specificity (43).
Recombinant Peptides and Proteins and MALDI-TOF-MS—Full-
length recombinant proteins were purchased (Peprotech, Rocky Hill,
NJ or R&D Systems, Minneapolis, MN), including human CCL-2
(hCCL-2; #300–04), mouse CCL-2 (mCCL-2; #250–10), mouse
CXCL-5 (mCXCL-5; #250–17), human FGF-21 (#100–42). Recombi-
nant synthetic peptides were synthesized by Mimotopes (Clayton,
Australia) for substrate validation. If the potential cleavage site was a
DPP cleavage event the first 15–20 amino acids of the mature N
terminus of the candidate substrate were synthesized, as we have
done previously (20, 21). Recombinant human FAP (rhFAP; #3715-
S.E.; R&D Systems), produced in baculovirus/Sf21 cultures, con-
sisted of 735 amino acids (Accession# Q12884; Leu26 to Asp760 with
N-terminal polyhistidine tag). This is a soluble form because it lacks
the N-terminal transmembrane domain.
Recombinant peptides and proteins at the stated amount were
incubated with rhFAP or buffer control in 25 mM Tris and 0.25 M NaCl
(pH 8.0) for up to 24 h at 37 °C. At each time point, a 1 l sample of
enzyme/substrate solution was pipetted onto the surface of a ground
steel target plate, allowed to dry and then overlaid with 0.5 l of
sinapinic acid matrix solution (10 mg/ml in a solution of 50:50 0.1%
trifluroacetic acid and 100% acetonitrile and then sonicated until
completely dissolved). Matrix-Assisted-Laser-Desorption-Ionisation
(MALDI) Mass Spectrometry analysis was performed as previously
described (7, 13). Once dry, the target plate was loaded into a Bruker
UltafleXtreme MALDI TOF/TOF (Bremen, Germany) and analyzed with
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the following settings: Linear mode, Mass Range 5–50 kDa, Detector
Gain 40	, Sample Rate 0.63 GS/s, Smartbeam Parameter “medium,”
Frequency 2000 Hz and realtime smoothing set to “high,” Laser shots
1000 (or 5	 1000 shots for dilute samples). Once mass spectra were
acquired, post processing was performed In Flex analysis (Bruker
Daltonics, Germany) with TopHat baseline subtraction followed by
spectral smoothing using 1 cycle of the Savitzsky Golay algorithm at
a width of 5 m/z. Peak detection was performed manually by labeling
the monoisotopic peak.
Immunoblotting—Whole cell lysates and CCM were made and
protein concentration was quantified using the Micro BCA Protein
Assay Kit (#3235; Thermo Scientific). 4–12% Bis-Tris SDS-PAGE
(NP0323PK2; Thermo Scientific) and immunoblotting was performed
as previously described (44). Primary antibodies were a goat poly-
clonal to mouse CSF-1 (AF416; R&D Systems) at 0.2 g/ml and a
rabbit polyclonal to LOX-L1 at 0.3 g/ml (NBP1–82827; Novus Bio-
logicals, Littleton, CO). Mouse monoclonal antibodies to GAPDH
(G8795; Sigma-Aldrich) at 0.1 g/ml and beta-actin (ab49900; Ab-
cam, Cambridge, MA) at 0.1 g/ml were internal loading controls.
Band intensity was quantified with Image J software (National Insti-
tutes of Health, Bethesda, MD).
Flow Cytometry—Flow cytometry methodology has been de-
scribed previously (28, 45, 46). FAP e and e MEFs were fixed in
2% (v/v) paraformaldehyde and stained with primary antibody against
human FAP (F19) at 2.99 g/ml (46) or the antibody against CSF-1 at
4 g/ml after cell permeabilization using 0.05% (w/v) saponin. Normal
mouse IgG (#12–371B, EMD Millipore) at 2.99 g/ml and goat IgG
(AB-108-C; R&D Systems) at 4 g/ml were used as negative controls,
respectively. The gating strategies are shown in supplemental Fig. S1.
A fluorescence signal from nonpermeabilized cells is indicative of
membrane expression.
Immunofluorescence Staining, Confocal Microscopy and Real Time
qPCR—The FAP e and e MEFs were stained with the F19 anti-
body and imaged using a Leica TCS SP5 confocal microscope as
described previously (44). Real time qPCR on DPP4, DPP8, and DPP9
were performed as described previously (47) using Taqman gene
expression assays (Applied Biosystems; Thermo Scientific), with
-actin as a standard.
Leukocyte Migration Assays—Neutrophils and monocytes were
isolated from mouse bone marrow as described previously (48, 49).
Bones harvested from C57BL/6J mice were crushed in sort buffer
(2.5% Fetal Bovine Serum [FBS, Hyclone, GE Life Sciences, Pitts-
burg, PA], 2 mM EDTA in PBS) followed by centrifugation at 500 	 g,
5 min, 4 °C. For monocyte isolation, cells were then resuspended in 4
ml PBS and underlaid with 3 ml Histopaque® 1083 (Sigma-Aldrich)
before centrifuging at 400 	 g, 30 min, 22 °C without braking. The
interface enriched with mononuclear leukocytes was carefully aspi-
rated and washed twice in 10 ml sort buffer at 500 	 g, 5 min, 4 °C.
For neutrophil isolation, cells were immediately subjected to red
blood cell lysis by adding 1.5 ml ACK lysis buffer (145 mM NH4Cl, 0.1
mM EDTA, 12 mM NaHCO3 in triple-distilled water) for 2.5 min at room
temperature before washing twice in 10 ml sort buffer at 400 	 g, 5
min, 4 °C. Cells were then stained at 4 °C for 50 min with the following
antibodies: B220 PE and APC (clone RA3–6B2, BD Biosciences, San
Diego, CA), CD115 PE (clone AFS98, eBioscience, San Diego, CA),
Ly6C FITC (clone HK1.4, BioLegend, San Diego, CA) and/or Ly6G
FITC and A647 (clone 1A8, BD). Cells were washed twice in 10 ml sort
buffer at 400 	 g, 5 min, 4 °C before resuspending in sort buffer
containing 0.5 g/ml DAPI (4,6-Diamidino-2-Phenylindole dihydro-
chloride, #D1306 Invitrogen, Eugene, OR). Monocytes or neutrophils
were subsequently sorted on a 7-laser Influx (BD) or 3-laser FACSAria
II (BD), whereby DAPI- live cells were initially selected, followed by the
exclusion of B220 and Ly6G cells. Subsequently, for monocyte
isolation, CD115 monocytes were selected, and for neutrophil iso-
lation, Ly6G neutrophils were selected. Cells were collected in 2 ml
FBS before usage for transwell migration assay. CytoSelect™ 24-well
cell migration assay with 5 m pore size (CBA-102, Cell Biolabs, Inc.,
San Diego, CA) was performed according to the manufacturer’s in-
structions (50). Sorted cells (1.5 	 106 cells/well) were added to the
insert and chemoattractant was added to the lower well of the migra-
tion plate. To examine monocyte migration, mCCL-2 was pre-incu-
bated with buffer or rhFAP at 37 °C for 24 h. Where FAP enzyme
activity was inhibited, FAP inhibitor ARI-3099 (51) at 20 M was
preincubated with rhFAP for 20 min at 37 °C. To examine neutrophil
migration, mCXCL-5 was preincubated at 37 °C for 24 h with buffer or
rhFAP in the presence of plasma from FAP enzyme-negative gene
knock-in (gki) mice (52). FAPgki mouse plasma contains naturally
occurring proteases and cytokines and so is a physiological environ-
ment for analyzing substrate cleavage. Cells were allowed to migrate
for 1.5 h at 37 °C, then cells from cells in the lower well, including cells
on the underside of the membrane, were lysed and stained with the
CyQuant® GR dye. Fluorescence was read with a fluorescence plate
reader at 480 nm excitation/520 nm detection (POLARstar Omega,
BMG Labtech). Chemotaxis index (fold change over the media con-
trol) was calculated.
Coagulation Assay—Wildtype (WT) and FAP GKO mice were anes-
thetized using isoflurane then blood was collected via cardiac punc-
ture into tubes at a ratio of 9:1 blood:citrate (3.5%; v/v). Plasma were
assayed for prothrombin time (PT) and activated partial thromboplas-
tin time (APTT) by the Institute of Hematology, Royal Prince Alfred
Hospital, Australia. Full blood counts on WT, DPP4 GKO and FAP
GKO mice were performed by veterinary pathology diagnostic ser-
vices of the University of Sydney.
Annotated spectra of the TAILS data and of the global quantitative
proteome comparison are provided at MS-viewer (54). The experi-
ments and the corresponding Search Keys are listed in supplemental
Table S1.
RESULTS
Generation of FAP Enzyme-active (e) and FAP Enzyme-
inactive (e) MEFs—To investigate the enzymatic activity of
FAP with a focus on identifying novel natural substrates of
FAP, cell lines suitable for proteomic and degradomic studies
were designed and produced. Uniquely, we used FAP GKO
cell lines so that substrates had no exposure to endogenous
FAP. We have detected no compensatory changes in DPP8,
DPP9 or DPP4 mRNA expression in FAP GKO mice (47).
Three biological replicates of the FAP e and e FAP MEF
cell lines were generated. Confocal microscopy (Fig. 1A) and
flow cytometry (Fig. 1B) indicated cell surface expression of
human FAP and intracellular expression of GFP by the FAP
e and FAP e mouse cell lines. FAP e and FAP e cells
expressed similar amounts of hFAP mRNA, and no hFAP
mRNA was detected in the empty vector control cells (Fig.
1C). Only whole live FAP e MEFs (Fig. 1D) and CCM (Fig. 1E)
contained FAP enzyme activity. These data confirmed the
MEF phenotypes and the serine to alanine catalytic inactiva-
tion of FAP.
Expression and activity levels of closely related proteases
were then measured in these cell lines, because when one
protease is downregulated, compensatory mechanisms might
upregulate enzymes that have similar functions. Specifically,
DPP4, DPP8, and DPP9 share DPP activity with FAP, and PEP
FAP Substrate Profiling
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FIG. 1. Validation of FAP expression in FAP e and FAP e MEFs. A, FAP e (left) and FAP e (right) transduced MEFs stained with the
F19 antibody that binds to human FAP (red). Cell nuclei were counterstained with DAPI (blue). Scale bars: 100 m. Confocal microscopy
images are representative of three replicate cell lines. B, F19 antibody stained cell surface FAP on FAP e (left; 99.7%) and FAP e (right;
92.2%) MEFs by flow cytometry. Mouse IgG was used as a negative control. C, qPCR of FAP mRNA expression in FAP e, FAP e and empty
vector control MEFs, normalized to the house keeping gene -actin. Mean  S.D.; n 
 3. D, E, FAP enzyme activity of FAP e, FAP e and
empty vector control MEFs was measured in a FAP-specific enzyme assay on whole live cells in PBS (D) and cell conditioned medium (CCM)
harvested from MEFs after 16 h serum starvation (E). Mean  S.E.; n 
 3; ns 
 not significant.
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exhibits comparable endopeptidase activity; although PEP,
DPP8, and DPP9 are exclusively intracellular (2, 4, 44, 55, 56).
We observed no significant difference in mRNA levels of dpp8
or dpp9, and dpp4 was downregulated to a small extent in the
FAP e MEFs compared with FAP e MEFs (supplemental
Fig. S2A). PEP activity was not detected in the CCM (supple-
mental Fig. S2B), so it would be very unlikely that this prote-
ase influenced the degradomic analyses of MEF CCM.
TAILS N-terminome Analysis on Secretomes of FAP e and
FAP e MEF Cell Lines—To identify FAP-dependent proteo-
lytic cleavage sites, we employed the TAILS method for an
N-terminomic analysis of CCM produced by FAP e MEFs
compared with FAP e MEFs. Three biological replicate anal-
yses were conducted. Identified N termini are summarized in
supplemental Tables S2–S4.
In line with earlier TAILS studies (57), we focused on protein
N termini that were identified in at least two replicates. Of
those 1914 N termini, 1340 mapped to proteins that are
annotated in Uniprot as being secreted but not exclusively in
exosomes. Compared with previous N-terminomic studies on
cultured cells, this was a high proportion of secreted or shed
proteins (58). Therefore, our statistical analysis focused on
cleavage sites in secreted or shed proteins.
To identify cleavage sites that significantly differ in their
abundance depending on FAP activity, we employed limma
statistics (59). Limma is superior to a classical Student’s t test
(e.g. with regard to multiple testing correction and prevention
of false-positive discoveries) (60) in the analysis of omics-style
data, which is characterized by a large number of analytes in
a small number of biological replicates (Fig. 2). We chose the
following criteria to distinguish significantly regulated cleav-
age sites: (1) limma moderated p value  0.05 and (2) average
increase or decrease in abundance by more than 50% (log2
(FAP-active/FAP-inactive)  0.58 for increase; log2 (FAP-ac-
tive/FAP-inactive)  0.58 for decrease. These strict criteria
highlighted 308 up-regulated and 278 downregulated cleav-
age sites upon increased FAP activity (limma statistics in
supplemental Table S5). Log-transformed fold-change distri-
butions before and after normalization appear in supplemental
Fig. S3.
Proteases act in networks with strong interdependency
(61). Often, altered activity of a protease under investigation
has downstream and secondary effects, e.g. stemming from
inactivation or activation of other proteases. The sequence
specificity of a cleavage site is a useful criterion to distinguish
direct substrates of a protease under investigation from
downstream effects (62).
FAP predominantly acts as an amino-dipeptidase with a
strong preference for P1 proline together with small amino
acids (mostly glycine, to a lesser extent alanine) in P2 (63).
Endoproteolytic activity has been reported as well (3), but in
an in vivo or cell-contextual setting, endoproteolytic activity of
FAP remains difficult to distinguish from primary cleavage
by a different endoprotease (e.g. a matrix metalloprotease
(MMP)), followed by processing of the neo N termini by FAP.
Specificity profiling of the 308 “upregulated” cleavage sites
that depend upon FAP activity highlights a noticeable prefer-
ence for P1 proline and P2 glycine (43) (Fig. 3A and 3B). These
data correspond to the reported Gly-Pro cleavage site spec-
ificity of FAP (12, 63, 64). These data also provide some
insight into the non-prime amino acids surrounding the cleav-
age site, including the unique observation of a preference for
serine or threonine in P1.
Identification of Candidate FAP Substrates by Parsing
TAILS Data—In the set of 308 “upregulated” cleavage sites
that depend on FAP activity, we focused on cleavage sites
with a P1 proline to identify bona fide FAP substrates.
Candidate Substrates Exhibiting Postproline Cleavage—
Following the criteria outlined above, 37 bona fide FAP cleav-
age sites were identified (Table I, supplemental Table S6).
FIG. 2. Proteomics and degradomics data. Volcano plot repre-
sentation of the comparisons of FAP-active and FAP-inactive MEF
secretomes following limma analyses of TAILS (A) and SILAC (B;
global proteomics).
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Among the candidate substrates is type 1 collagen (CN-I),
which is a well-known substrate of FAP (1, 12). Thus, identi-
fication of neo-N termini produced from cleavage events after
a proline in CN-I from the FAP e secretome acted as an
internal positive control and demonstrated the reliability of the
TAILS method. Cleavage events were also observed in colla-
gen types III and V.
Further FAP cleavage sites in extracellular matrix compo-
nents were found in fibrillin-2 and extracellular matrix protein
1 (ECM-1). In fibrillin-2, the cleavage occurred at position 60,
in the propeptide domain, after a Gly-Pro sequence. In
ECM-1, cleavage occurred at position 142 after a Lys-Pro
sequence, which renders a preceding cleavage by a different
endoprotease likely. Cleavage of lysyl oxidase homolog 2
(LOX-L2) by FAP was seen near the genome-encoded N
terminus at position 36 after a Tyr-Pro sequence that follows
the signal peptide.
In addition, there was prominent processing of complement
C1q tumor necrosis factor-related protein 6 (C1qT6) by FAP at
position 26 after a Val-Pro sequence. After removal of the
signal peptide, secreted C1qT6 commences with this Val-Pro
sequence. Thus, FAP acts as an aminodipeptidase on C1qT6.
Lastly, TAILS provided evidence for processing by FAP of
CXCL-5 at position 42, which is after an Ala-Pro sequence.
CXCL-5 has an unusually long signal peptide of 40 residues,
so Ala-Pro is the N terminus of secreted CXCL-5. Thus, FAP
acts as an aminodipeptidase on CXCL-5.
Cleavage Sites Lacking a P1 Proline That Are Affected By
FAP Activity—FAP activity had a strong effect on numerous
cleavage sites that do not represent its known active site
specificity. There are clear data that FAP can cleave post-
alanine as well as post-proline (21, 22), but cleavage after
other residues may be downstream effects of FAP rather than
substrates directly hydrolyzed by FAP. Nevertheless, this
“downstream degradome” constitutes an important aspect of
FAP biology. For example, FAP activity leads to substantially
elevated levels of MMP-1 in cancer-associated fibroblasts
while simultaneously reducing the levels of tissue plasmino-
gen activator (tPA) (63). MMP-1 and FAP co-operatively digest
collagen (12).
Many neo-N termini lacking a P1 proline were affected by
FAP activity (supplemental Table S5). These include the ECM
proteins fibronectin, CN -I, -III, -V and -VI, laminin, fibulin -1,
-4 and -7, fibrillin -1 and -2, filamin -A and -B, plectin, perios-
tin, procollagen C-endopeptidase enhancer 1, the MMP in-
hibitor TIMP-1, and LOX-L1 and LOX-L2. The LOX enzymes
are extracellular copper-dependent amine oxidases that cat-
alyze the first step in the formation of crosslinking in collagens
and elastin. LOX enzymes, TIMPs and MMPs alter the ECM,
so FAP enzyme activity dependent changes in the relative
abundance of any of those enzymes are very likely to cause
FAP enzyme activity dependent indirect alterations of abun-
dance or properties of many ECM proteins in CCM.
SILAC Applied to FAP e and FAP e MEF Secretomes
and Identification of Candidate FAP Substrates—TAILS high-
lighted that FAP activity had a pronounced impact on cell-
contextual extracellular proteolysis. This finding prompted us
to investigate effects of FAP activity on the composition of the
MEF-derived cell conditioned medium (CCM) (“secretome”).
For this purpose, we employed a QSTAR device, which was
enough for medium proteome coverage. In data interpreta-
tion, we were particularly interested in the altered abundance
of proteases and protease inhibitors. Differential quantitative
proteomics used SILAC in five biological replicates (proteins
listed in supplemental Tables S7–S11; peptides listed in sup-
plemental Tables S12–S16).
FIG. 3. Understanding the cleavage site specificity of FAP.
Graphical representation of the FAP e secretome specificity profile
of peptides following limma analysis of TAILS. A, A heatmap of the
occurrence of amino acids in each position, P6-P6, relative to
the natural abundance levels of amino acids in the mouse (93). The
cleavage site specificity of FAP shows preferences for proline (P) in
P1 (12.3%). B, Dependence plot displaying the amino acid occur-
rence (%) at positions P3-P3 when proline is fixed at position P1.
There was an 83.8% likelihood of glycine in position P2 when proline
is at P1.
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As outlined for the TAILS approach, we employed limma
statistics to delineate proteins that displayed significantly af-
fected abundance in the presence of FAP enzyme activity. We
chose the following criteria to distinguish significantly regu-
lated proteins: (1) identification and quantitation in at least
three replicate experiments, (2) annotation as a secreted or
shed protein, (3) limma moderated p value  0.05 and (4)
average increase or decrease in abundance by more than
50% (log2 (FAP-active/FAP-inactive)  0.58 for increase; log2
(FAP-active/FAP-inactive)  -0.58 for decrease). These crite-
ria highlighted 31 more abundant and 33 less abundant pro-
teins with increased FAP activity (limma statistics in supple-
mental Table S17).
Proteins That Were Differentially Abundant In the FAP e
MEF secretome—Compared with FAP e, the FAP e secre-
tome contained more MMP-2 (“72 kDa type IV collagenase”)
and MMP-3 (Stromelysin-1). In addition to our initial interest in
proteases and their inhibitors, we observed increased levels
of CSF-1 and monocyte chemoattractant protein-1 (MCP-1/
CCL-2) (plimma 
 0.055 - but increased in all 5 replicates and
further considered because of its biological importance). This
impact on CCL-2 is similarly observed in cancer associated
fibroblasts (CAFs), where FAP activity leads to substantially
elevated levels of CCL-2 (63).
Among proteins that were less abundant in the secretome
of FAP e compared with FAP e MEFs of particular interest
were annexins A1 and A2 and the collagen - binding protease
inhibitor serpin H1 (also seen with limma statistics on TAILS
data; supplemental Table S5).
Validation of Candidate Substrates Found By TAILS—Se-
lected candidate substrates identified through TAILS analysis
were analyzed by in vitro cleavage assay. Recombinant pro-
teins or synthetic N-terminal peptides corresponding to the
secreted form of the protein were incubated with recombinant
human FAP (rhFAP), and cleavage was then monitored over
time by MALDI-TOF-MS analysis.
Secreted CXCL-5 (41–132) has Ala-Pro at the N terminus
that TAILS identified as removed by FAP (Fig. 4A). In vitro
cleavage using recombinant mouse CXCL-5 validated that
observation. All the CXCL-5 lacked the Ala41-Pro42 after 24 h
incubation with rhFAP (Fig. 4B). To examine a biological out-
come of FAP-mediated cleavage in ex vivo physiological con-
ditions, neutrophil migration assays were performed using
CXCL-5 pre-incubated with FAP gki plasma, into which rhFAP
or buffer (control) was added (Fig. 4C). The naturally occurring
CXCL-5 in the FAP gki plasma increased neutrophil migration
by 2-fold. Following FAP-mediated cleavage, the chemotactic
activity of CXCL-5 was not altered (Fig. 4C).
C1qT6 is a 264 - residue protein of four domains and the
secreted protein begins with a Val25-Pro26 sequence (Fig.
5A) that TAILS identified as removed by FAP. FAP-cleavage of
C1qT6 was confirmed in vitro (Fig. 5B) using a synthetic
peptide that represents the N-terminal 21 residues of se-
creted C1qT6 (25–45). Incubation with rhFAP yielded a cleav-
age product with a reduced mass of 218 Da within 5 min, with
the mass shift corresponding to the removal of Val-Pro. The
peptide was almost completely converted to 218 Da by 10
min (Fig. 5B), and within 30 min N-terminal processing of the
C1qT6-derived peptide was complete (data not shown). This
in vitro cleavage assay substantiates the enzymatic ability of
FAP to process the N terminus of C1qT6.
The cleavage of LOX-L1 was observed at position 511 after
a Lys-Ala sequence, with a  50% average increase in abun-
dance of the cleaved form (p  0.05) (supplemental Table S5).
Immunoblotting detected more LOX-L1 in the FAP e than in
the FAP e MEF CCM (Fig. 6). The whole cell lysates lacked
this difference between the FAP e and e MEFs (Fig. 6),
consistent with the cleavage of LOX-L1 by FAP occurring
extracellularly.
Confirming FAP Alters the MEF Secretome—The secre-
tome analysis highlighted elevated levels of shed CSF-1 in the
FAP e MEF secretome (supplemental Table S17). CSF-1 is
important in the proliferation, differentiation, and survival of
monocytes and macrophages. CSF-1 is a type I cell-surface
protein that is released into the extracellular milieu by endo-
proteolytic shedding. We therefore probed cell-surface levels
of CSF-1 using flow cytometry analysis and an antibody spe-
cific for the (potentially shed) N terminus of CSF-1 (Lys33-
Glu262). That analysis showed 5-fold more cells immunopo-
sitive for CSF-1 in the FAP e than in the FAP e MEF (Fig.
7A). Concordantly, immunoblotting on MEF cell lysates for
CSF-1 showed that more cellular CSF-1 was in FAP e than
e MEFs (Fig. 7B). A possible explanation is that elevated
shedding of CSF-1 in the FAP e MEFs leads to its depletion
from the cell surface.
However, our data do not show that FAP directly acts as a
CSF-1 sheddase. Although one TAILS experiment identified a
P1-Pro, FAP-dependent cleavage site in CSF-1 in proximity to
its annotated shedding site (Fig. 7C), FAP did not cut a syn-
thetic peptide sequence that encompasses this sequence
motif (Fig. 7D). Therefore, the impact of FAP on CSF-1 shed-
ding is possibly indirect.
The present and previous proteomic studies strongly indi-
cate that FAP activity results in increased levels of CCL-2 (63).
Both human and mouse CCL-2 proteins have potential post-
proline cleavage sites after Gln24-Pro25 and Ala30-Pro31.
Full-length human and mouse CCL-2 were incubated with
rhFAP and specific cleavage after Proline31 was shown by
LC-MS/MS (Fig. 8A–8C). Monocyte migration assays as-
sessed biological effects of this cleavage event. CCL-2 was
able to induce monocyte migration. However, FAP, with or
without the presence of a FAP specific inhibitor, did not alter
the chemotactic activity of CCL-2 (Fig. 8D).
Candidate Substrates from Data Mining—Data mining and
literature-based approaches were also utilized to search for
candidate FAP substrates. FGF-21 was chosen as a candi-
date FAP endopeptidase substrate. Unlike most other candi-
date substrates, the cleavage site within FGF-21 is located
FAP Substrate Profiling
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within a dozen residues of the C- rather than N terminus (Fig.
9A). Recombinant human FGF-21 (hFGF-21) matching resi-
dues 29–209 (lacking the signal peptide) was analyzed in
MALDI-TOF-MS and LC-MS/MS analyses to investigate
whether this protein undergoes FAP cleavage. By MALDI, the
doubly charged ion was identified (peak at 9785 Da) and
after 10 min incubation with FAP a smaller peak correspond-
ing to hFGF-21 lacking the last 10 amino acids (9296 Da)
was observed, and after 2 h incubation hFGF-21 was com-
pletely digested by FAP (Fig. 9B). No cleavage was observed
in the absence of FAP (data no shown). To confirm hFGF-21
as a FAP substrate in vitro, LC-MS/MS analysis was per-
formed using the enzyme AspN rather than trypsin. Only
AspN-cleaved peptides were identified in the control. In
the FAP-treated sample the peptide C-terminal to the cleav-
age site was identified but the peptide N-terminal to this
cleavage site was not detected. However, 33.7% sequence
coverage of FGF-21 was observed in the untreated sample,
whereas only 5.5% sequence coverage was observed in the
FAP-treated sample. Taken together, the LC-MS/MS data and
MALDI-TOF-MS data demonstrated that hFGF-21 undergoes
in vitro cleavage by FAP after proline 171 (Fig. 9C).
Influence of FAP on Coagulation—The present work high-
lights a strong impact of FAP on extracellular proteolysis (both
directly and indirectly). Cleavage of human 2-antiplasmin by
FAP has implicated the activity of FAP in fibrinolysis (14). In
the present study, FAP affected the proteolytic processing of
several mouse proteins with functions in coagulation, such as
prothrombin and thrombospondin-2 (supplemental Table S5),
indicating that FAP might influence coagulation. Therefore,
plasma was isolated from WT and FAP GKO mice and pro-
thrombin times (PT) and activated partial thromboplastin
times (APTT) were measured. PT examines the extrinsic co-
agulation pathway, whereas APTT test examines the intrinsic
coagulation pathway. No significant difference in prothrombin
times between WT and FAP GKO mouse plasma was ob-
served (Fig. 10A). However, a significant increase in activated
partial prothrombin times was observed in the FAP GKO
plasma compared with WT plasma (p 
 0.033; Fig. 10B).
Full blood counts on WT and FAP GKO mice showed no
difference in platelet numbers or any other major blood cell
type (supplemental Table S18), which is consistent with the
initial description of this mouse strain (24, 65).
DISCUSSION
A large number of FAP-driven cleavage events were iden-
tified using TAILS. A strength of the approach taken was the
production of a cellular source of substrates, from GKO
MEFs, that had never been exposed to FAP or its enzyme
activity. Many of the detected cleavage events are likely to be
direct cleavage by FAP, whereas others may be caused indi-
rectly. Global differential proteomics showed differential
abundance of several proteases and protease inhibitors that
probably contributed indirect cleavage events to our data.
Much of the detected post-proline cleavage by FAP was of
collagens and other ECM proteins, including CN-I, CN-III,
CN-V, fibrillin-2 and ECM-1 (Table I). Fibroblasts are the main
cellular source of ECM proteins, so it is sensible that many
ECM proteins were detected in CCM from MEFs. Neverthe-
less, the preponderance of ECM associated candidate sub-
strates was the dominant finding of this study.
In addition, many proteolytic events were observed in a
range of ECM proteins that did not correspond to post-proline
processing, suggesting either that FAP is not restricted to
cleavage after a proline and/or that FAP drives increased
levels of other ECM - degrading proteases. The many ECM
associated proteins identified as differentially abundant in-
clude collagens, laminins, fibronectin, periostin, cofilin-1, ca-
thepsin-B, fibrillin-1, fibulin-1, ECM-1, serpin-H1, LOX-L1,
NCAM-1 and the ECM degrading enzymes MMP-2 and
MMP-3 and MMP inhibitors TIMP-1 and TIMP-2, in the FAP
e or FAP e secretome (supplemental Table S17). These
data may point to a FAP-MMP-TIMP axis of ECM regulation.
The lysyl oxidases are of particular interest because they drive
collagen crosslinking (66), which is crucial in liver fibrosis (67).
In addition to directly causing degradation of LOX-L1 (Fig. 5),
we saw that FAP altered the levels of BMP-1 and periostin
(supplemental Table S17), which can promote LOX activation
(68). Considered together, the data suggests that when FAP
e is expressed it results in greater levels of ECM proteolysis,
ECM degrading enzymes and their inhibitors and other ECM
associated proteins, which points to a significant role for FAP
in the regulation of ECM degradation. These insights are
consistent with the known importance of FAP in ECM-de-
pendent cancer cell and fibroblast invasion and migration (28,
69–72) and more generally in cell - ECM interactions (4, 12,
73, 74). Annexin A2 is involved in fibrinolysis (75), and has
been shown to interact with FAP (76, 77). Several proteins
found to be cut or differentially abundant in the presence of
FAP enzyme activity are important in liver fibrosis, including
CYR-61 (CCN-1) (78, 79), and in iron storage, including fer-
ritins and lipocalin (LCN2) (80). These data, together with a
recent study (63), highlight that differential FAP activity has a
profound effect on the secretome, hence characterizing FAP
as a key player in shaping the pericellular environment.
Post-translational modifications (PTM) modify proteins in-
cluding interaction between a substrate and an enzyme. Al-
though synthetic proteins or peptides may not possess PTM
FIG. 4. In vitro examination of candidate substrate CXCL-5. A, Schematic of the genome - encoded primary structure of mouse CXCL-5.
The Uniprot-annotated N-terminal sequence is shown with the proposed FAP cleavage site indicated by a red arrow after Pro42. B,
MALDI-TOF-MS spectra showing removal of Ala-Pro from the N terminus of mCXCL-5. C, Neutrophil migration assay using mCXCL-5
pre-incubated with FAPgki plasma, with rhFAP or buffer (control), at 37 °C for 24 h. Data are representative of two independent experiments.
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that occur in vivo, they are often useful for initial substrate
validation. Mouse CXCL-5 contains a DPP substrate cleavage
site at Ala-Pro at the N terminus after the signal peptide is
removed. The secreted form of mCXCL-5 has 92 amino acids
(41–132) and can be further cleaved into two isoforms that
have 78 residues (41–118) and 70 residues (49–118) respec-
tively. These truncated isoforms are more potent than the
secreted CXCL-5 (41–132) at inducing neutrophil infiltration in
vitro (81). Because the FAP cleavage site is quite close to the
ELR motif that is important for receptor binding, FAP-trun-
cated CXCL-5 might show enhanced chemotactic activity as
well. However, neutrophil chemotaxis was not different be-
tween intact and FAP-truncated CXCL-5. Thus, dipeptide re-
moval from the N terminus of CXCL-5 does not affect the
biological potency of this chemokine.
C1qT6 is a clear candidate substrate, with the mature N
terminus present in the FAP e secretome and the protease-
generated neo-N terminus in the FAP e secretome (Fig. 4).
C1qT6 is a member of the C1q/TNF-related protein (CTRP)
family, which contains adiponectin (82). C1qT6 also has roles
in coagulation and arthritis (83), possibly hepatocellular car-
cinoma (84), and metabolic disorders (85). Although removal
of just two N-terminal amino acids might not have a signif-
icant effect on C1qT6, because the known biological func-
tion of this protein is induced via its C-terminal domain (86),
DPP cleavage of C1qT6 might confer upon this protein
increased susceptibility to further digestion by other pro-
teases, leading to production of the naturally occurring trun-
cated form.
The in vitro endopeptidase cleavage by FAP of both human
and mouse CCL-2 (Fig. 7) is the first report of a natural FAP
endopeptidase substrate being cleaved after an alanine-pro-
line sequence. CCL-2 has ubiquitous pro-inflammatory ac-
tions (70, 87, 88) through binding to its cognate receptor
CCR2. Removing the first 8 amino acids off the N terminus of
CCL-2 converts it into a receptor antagonist that retains the
ability to bind to CCR2 but not the ability to elicit a chemot-
actic response (87, 89). Therefore, a truncated CCL-2 analog
has been developed as an anti-inflammatory therapeutic (90,
91). The cleavage of CCL-2 by FAP, resulting in the removal of
the first 8 amino acids, would convert it into a dominant
negative receptor antagonist. However, chemotaxis ability of
FIG. 5. In vitro examination of candidate substrate C1qT6. A, Schematic of the primary structure of mouse C1qT6. The Uniprot-annotated
N terminus sequence is shown with proposed FAP cleavage site indicated by a red arrow after Pro26. The peptide identified from TAILS
analysis and the corresponding fold changes are shown. Mean  S.D.; n 
 2–3. B, MALDI-TOF-MS spectra showing removal of Val-Pro
dipeptide from the N terminus of synthetic recombinant peptide, consistent with a peak shift of 203. The peptide was almost completely
cleaved at 10 min. The synthetic peptide had two forms, which differed in mass by 22 daltons as indicated by the presence of two peaks.
Both forms were hydrolyzed by FAP.
FIG. 6. In vitro examination of candidate substrate LOX-L1. A, Schematic of the primary structure of mouse LOX-L1. The Uniprot-
annotated protein sequence is shown with the proposed FAP cleavage site indicated by red arrows. B, LOX-L1 immunoblotting of whole cell
lysates and of cell conditioned medium (CCM) from the FAP e and e MEFs. C, Densitometry was performed using beta-actin as loading
control. The data are representative of three independent experiments.
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intact or FAP-cleaved CCL-2 in monocytes was not changed,
indicating that FAP derived cleavage of CCL-2 does not reg-
ulate the bioactivity of this chemokine.
Recently, FGF-21 cleavage by FAP has been reported (8–
10). Such cleavage was also observed here, by LC-MS/MS
coupled with MALDI-TOF-MS, showing that human FGF-21
undergoes cleavage by FAP after Pro171 in vitro (Fig. 9).
Administering a selective FAP inhibitor acutely increases cir-
culating intact FGF-21 levels in cynomolgus monkeys (8) and
prolongs the half-life of circulating human FGF-21 in mice
(10), therefore FGF-21 is a physiological substrate for FAP.
Proteins that were identified by TAILS and have roles in lipid
or energy metabolism include proprotein convertase subtili-
sin/kexin type 9 (PCSK-9), pyruvate kinase PKM, insulin-2,
PYY, clusterin (apolipoprotein J) and low-density lipoprotein
receptor 8 (LRP-8) (supplemental Table S5). Thus, FAP may
have important influences on energy metabolism.
FAP has a well-established role in clotting and fibrinolysis in
humans and this role is mediated by cleavage of 2-antiplas-
min (11, 14), but other FAP-interacting molecules might be
involved (77). Mouse 2-antiplasmin lacks the FAP cleavage
site and a role for FAP in clotting in the mouse had not been
reported. However, our degradomics and proteomics data
pointed to the potential for a role for FAP in coagulation in the
mouse. Concordantly, we observed that, as in humans (14),
depletion of FAP from plasma slows the clotting time in mice
(Fig. 10). The proteins that we identified as potentially me-
diating this physiological outcome are FSTL-1 (92), C1qT6
(83), SNED-1, filamin-A, serpin-G1, thrombospondin-1,
thrombospondin-2, and PAI-1 (supplemental Tables S5 and
S17). Our finding that mouse plasma that lacks FAP exhib-
ited slowed coagulation is consistent with the identification
of a number of potential FAP substrates that are coagulation
- associated.
FIG. 7. In vitro examination of candidate substrate CSF-1. A, CSF-1 primary antibody paired with a secondary anti-goat Alexa Fluor
647 stained the N terminus of CSF-1 in the FAP e and e MEFs after permeabilization with 0.05% (w/v) saponin. 23.7% of FAP e MEFs
were immunopositive compared with only 4.5% of the FAP e MEFs. Goat IgG was used as a negative control. B, Immunoblotting of
CSF-1 in whole cell lysates revealed more cellular CSF-1 present in FAP e MEFs than FAP e MEFs. Densitometry was performed using
GAPDH as a loading control. (A, B) Representative of two independent experiments. C, Schematic of the primary structure of CSF-1. The
Uniprot-annotated N terminus sequence is shown with the proposed FAP cleavage site indicated by a red arrow after Pro449. This
cleavage site identified in TAILS is in the extracellular region, near the transmembrane domain. Identified peptide from TAILS analysis and
its corresponding fold change are shown. Synthetic recombinant peptide consists of Ser442 to Arg463, with the proposed FAP cleavage
site indicated by a red arrow. D, MALDI-TOF-MS showing no cleavage of the synthetic recombinant CSF-1 peptide after 16 h incubation
with rhFAP at 37 °C.
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This study focused on identifying novel substrates of FAP
and the downstream effects of FAP enzyme activity on the
MEF secretome. Many potential FAP substrates were identi-
fied, including many ECM and immunoregulatory proteins,
and several were confirmed that may have implications for the
role of FAP in health and disease. Future investigations into
which natural substrates are indirectly cleaved, via other en-
FIG. 7—continued
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FIG. 8. In vitro examination of
candidate substrate human CCL-
2 (hCCL-2) and mouse CCL-2
(mCCL-2) using LC-MS/MS. A,
Schematic of the primary structure of
hCCL-2. The Uniprot-annotated N
terminus sequence is shown with the
proposed FAP cleavage site indi-
cated by a red arrow after Pro31. B,
C, Database-derived amino acid se-
quences of recombinant hCCL-2 (B)
and mCCL-2 (C) are shown with red
arrows indicating the FAP cleavage
sites. The peptide sequence that is
colored red corresponds to a peptide
produced by FAP-mediated cleav-
age. Black and gray alternating pep-
tides represent the peptides poten-
tially produced by digestion with
trypsin. Recombinant hCCL-2 and
mCCL-2 were incubated with rhFAP
( FAP) or a buffer control (no FAP)
for 4 h at 37 °C. Samples were then
treated with trypsin and analyzed by
LC-MS/MS. 98% sequence coverage
of hCCL-2 was observed in both
samples, whereas 14% sequence
coverage of mCCL-2 was seen, and
the truncated peptides matching to
the FAP-cleavage products were
identified only in the samples that had
been treated with FAP. Some trypsin
cleavages were missed (*). Repre-
sentative data from two technical
replicates. D, Monocyte migration as-
say using mCCL-2 pre-incubated at
37 °C for 24 h with buffer (control),
rhFAP, or rhFAP with a specific FAP
inhibitor (FAPi). Data are representa-
tive of two independent experiments.
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zymes, rather than by direct FAP-mediated cleavage, may
provide greater understanding of the pathogenesis of tumors
and of fibrotic disorders.
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FIG. 9. In vitro examination of candidate substrate human FGF21 (hFGF21). A, Schematic of the primary structure of hFGF21. The
Uniprot-annotated N terminus sequence is shown with proposed FAP cleavage site indicated by a red arrow after Pro199. B, MALDI-TOF-MS
spectra showing cleavage after Gly-Pro199. The 9786 Da peak corresponds to the doubly charged full-length protein. After 10 min incubation
with rhFAP at 37 °C, cleavage resulted in the 9296 Da peak corresponding to the full-length protein lacking the last 10 amino acids. FGF-21
was fully digested at 120 min incubation with rhFAP. C, Database-derived amino acid sequence of rhFGF21, with a red arrow at the FAP
cleavage site and the red peptide corresponds to the peptide produced from FAP cleavage. Black and gray alternating peptides represent the
peptides produced after digestion with AspN. Recombinant hFGF21 was incubated with rhFAP ( FAP) or a buffer control (no FAP) for 30 min
at 37 °C, digested with AspN and analyzed by LC-MS/MS. The peptides identified in each sample are listed; 33.7% sequence coverage of
rhFGF21 was observed in the untreated sample whereas only 5.5% sequence coverage was observed in the rhFAP-treated sample, and the
truncated peptide matching to the FAP-cleavage product was identified only in the sample that was treated with rhFAP. Representative of two
technical replicates.
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FIG. 10. Influence of FAP on the extrinsic and intrinsic coagu-
lation pathways. Plasma was collected from wild type (WT) and FAP
gene knockout (GKO) mice and prothrombin times (PT) and activated
partial thromboplastin times (aPTT) were measured. A, No significant
difference in prothrombin times between WT and FAP GKO mouse
plasma was observed. B, A significant increase in activated partial
prothrombin times was observed in the FAP GKO plasma compared
with WT plasma (p 
 0.0325). Mean  S.E., n 
 5–7.
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